Eli Lilly (LLY) and Boehringer Ingelheim's empagliflozin drug reduced blood pressure in patients...


Eli Lilly (LLY) and Boehringer Ingelheim's empagliflozin drug reduced blood pressure in patients with Type II diabetes in two Phase IIb trials. Meanwhile, the companies' Analogue insulin performed well in a Phase II study, as did the already-approved Tradjenta for controlling blood sugar levels in elderly patients with type 2 diabetes in three trials.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs